Background: In a 2008-10 study, we found a pretreatment HIV drug resistance (PDR) prevalence of 18.2% in patients at Bugando Medical Centre (BMC) in Mwanza, Tanzania.
Introduction
The roll-out of ART is one of the major success stories of global health. In Tanzania, 690 000 patients were receiving antiretroviral drugs (ARVs) by the end of 2015, 1 compared with 19600 in 2005. 2 This trend will continue as Tanzania works towards the goal of 90% of tested HIV-positive people being on ART, within the 90-90-90 strategy of the Joint United Nations Programme on HIV/ AIDS. However, increased access to ART is likely to be associated with an increase in HIV drug resistance (HIVDR).
3,4 Therefore, the WHO recommends that scaling up of ART should be accompanied by surveillance of both pretreatment HIVDR (PDR) and of HIVDR acquired under ART. 4 PDR testing is currently not recommended by the Tanzanian guidelines 5 and data about PDR in Tanzania are very sparse. Most studies report rates from 2004 to 2007, shortly after the roll-out of ART in 2004, when drastically fewer people were on ART and different ARVs were used. Only three studies report more recent data. Masimba et al. 6 and Vairo et al. 7 found prevalences of PDR of 11.9% and 3.3% in 119 and 67 treatment-naive patients from 2009 and 2010-11, respectively. We found a prevalence of PDR of 18.2% in treatment-naive patients at Bugando Medical Centre (BMC) in 2008-10. 8 The WHO recommends that PDR surveys should be repeated every 3 years, 4 and re-surveying seems especially appropriate if earlier studies reported high prevalence rates.
PDR can be caused by transmission of resistant HIV strains [i.e. transmitted HIVDR (TDR)] or generated intra-patient by exposure to ARVs, such as in prevention of mother-to-child transmission (PMTCT), pre-or post-exposure prophylaxis, self-medication or previous prescribed ART.
The aim of this study was to determine the prevalence, pattern and trend of PDR and TDR in patients attending the HIV Care and Treatment Centre (CTC) at BMC in Mwanza, Tanzania, from 2013 to V C The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com J Antimicrob Chemother 2018; 73: 3476-3481 doi:10.1093/jac/dky332 Advance Access publication 27 August 2018 2015. The analysis was conducted in accordance with WHO recommendations for the surveillance of PDR 9 and TDR. 10 
Patients and methods

Study population
This cross-sectional study was conducted at the CTC at the tertiary consultant and academic teaching hospital BMC in Mwanza, Tanzania. Participants were confirmed HIV-positive patients older than 18 years and ARV naive, except for temporary ARV use in the context of PMTCT, which was not an exclusion criterion. Four hundred and six patients were sequentially enrolled into two groups: 196 patients initiating ART (ART-initiator group) and 210 patients attending the CTC for control examinations, not initiating ART (non-initiator group). Patients qualified for the ART-initiator group if they started ART within 90 days after blood sampling, judged by information in the medical records. We obtained sequences from 97 patients of the non-initiator group and 138 of the ART-initiator group.
Data collection and blood sampling
Demographic and clinical data were collected from questionnaires, medical records and the electronic patient database of the CTC. Twenty-one millilitres of blood per patient was collected, centrifuged and frozen in cryotubes at #20 C. The specimens were then transported by World Courier in a #20 C cold chain to Germany.
Sequencing
HIV nucleic acid was isolated from plasma using a QIAamp MinElute Virus Spin Kit and HIV pol sequences were amplified by RT-PCR and HIV pol-specific PCR followed by nested PCR as previously described. 11 Positive PCRs were sequenced with the ABI Prism 310 Genetic Analyzer system.
Sequence analysis
PDR (in accordance with WHO guidelines 9 ) was defined as low-, intermediate-or high-level resistance (mutation score 15 in Stanford's HIVDR database 12 ) for one of the following drugs: any nucleoside or nucleotide reverse transcriptase inhibitor [N(t)RTI], nevirapine, efavirenz, darunavir/ritonavir, lopinavir/ritonavir or atazanavir/ritonavir. TDR (in accordance with WHO guidelines 10 ) was defined as the presence of at least one of the standard surveillance drug-resistance mutations, 13 analysed with the calibrated population resistance tool. 
Data processing and statistical analysis
Patient data were transferred to duplicate Microsoft Excel tables. Statistical analysis was performed using SPSS (version 24, IBM) and 95% CIs were calculated with Wilson's method. Patient characteristics were tested for influence on HIVDR prevalence using Fisher's exact test (categorical variables) and/or binomial logistic regression using the Wald v 2 test (ordinal and continuous variables).
Ethics
The study was approved by the Catholic University of Health and Allied Sciences (CUHAS)/BMC Research Ethics Committee (CREC) (CREC/021/2013) and the Lake Zone Institutional Review Board of the National Institute for Medical Research, Tanzania (MR/53/100/294). All patients gave written informed consent. All clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki.
Terminology
The term 'PDR' often refers to resistance at the time of ART initiation. For simplicity, we also use it for patients not initiating ART.
Results and discussion
Patient characteristics
Demographic and clinical data are displayed in Table 1 . We had already conducted a study on PDR prevalence, with similar inclusion criteria, at BMC in 2008-10. 8 Patient characteristics of the two study groups were similar.
HIV-1 subtypes
The most common subtype, A, was found in 46.0% of the samples, followed by C in 33.2%, D in 17.0% and B in 3.4% (Table 1 ). This is a typical subtype distribution for this area. 8, 15 Prevalence and patterns of PDR
The point prevalence of PDR in our sample was 4.7% (11/235; 95% CI 2.6%-8.2%) ( Table 2 ). PDR prevalence was 3.1% (3/97; 95% CI 1.1%-8.7%) for the non-initiators and 5.8% (8/138; 95% CI 3.0%-11.0%) for the ART initiators. The WHO outcome 1b, 'prevalence of HIVDR among ART initiators without prior exposure to ARVs', 9 was 6.3% (8/128; 95% CI 3.2%-11.8%). PDR to N(t)RTIs, NNRTIs and PIs was found in 1.7% (4/235; 95% CI 0.7%-4.3%), 3.0% (7/235; 95% CI 1.5%-6.0%) and 0.0% (0/235; 95% CI 0.0%-1.6%) of patients, respectively. Dual class resistance was not observed.
The most frequent mutation was K103N, which was found in 2.1% (5/235; 95% CI 0.9%-4.9%) of patients. Other mutations detected were M41L and A98G (both 3/235; 1.3%; 95% CI 0.4%-3.7%) and K65R and V108I (both 1/235; 0.4%; 95% CI 0.1%-2.4%). This, and the absence of PI-associated mutations, is consistent with our previous observations. 8 The absence of the lamivudineassociated mutation M184V is surprising given the extensive use of lamivudine in Tanzania, and not consistent with our previous results.
In the publication of our 2008-10 study, 8 we used a slightly different definition of PDR. When we re-analysed the sequences according to the definition used here, the prevalence of PDR was 17.0% (15/88; 95% CI 10.6%-26.2%), and significantly higher than the prevalence found in 2013-15 ( Figure 1 ) (P , 0.001, Fisher's exact test). Several factors might have contributed to this decrease in PDR prevalence. Toxic stavudine-based ART regimens were phased out in 2012-15 and replaced with single-pill, tolerable tenofovir disoproxil fumarate-based regimens. Adherence monitoring by HIV viral load testing was introduced. More efficient supply chain management of ARVs reduced the frequency of stock running out. Increased access to free ART services led to a reduction in the use of suboptimal ARV doses as a result of sharing or purchase of insufficient doses.
16,17
Prevalence of TDR The prevalence of TDR was 6.0% (14/235; 95% CI 3.6%-9.8%). Most patients that had TDR also had PDR and vice versa. Exceptions were patients infected with viral strains carrying the mutations A98G/V108I (PDR but not TDR, two patients) and I85V/G73S/M46I Pretreatment HIV drug resistance in Mwanza, Tanzania Pretreatment HIV drug resistance in Mwanza, Tanzania JAC (TDR but not PDR, five patients). A98G and V108I mediate resistance to efavirenz and nevirapine, 18 but occur at polymorphic positions and are therefore not included in the WHO surveillance list for TDR. 13 I85V and G73S are non-polymorphic and selected by PIs, 13 but confer only very weak resistance to the PIs relevant for WHO-defined PDR. 18 Prevalence of HIVDR to other ARVs An additional 6.0% (14/235; 95% CI 3.6%-9.8%) of patients did not fall under the criteria for PDR or TDR, but carried viral strains resistant to other ARVs (mutation score 15 in Stanford's HIVDR database; 12 data not shown). The mutations were E138A (13 patients) and E138G (1 patient). E138A is present in 5% of treatment-naive patients and most common in subtype C. 19 It conveys resistance to rilpivirine and etravirine, 19 with implications for future use in resource-limited settings. Etravirine is proposed to be included in third-line ART regimens in Tanzania.
JAC
Risk factor analysis
Prevalence of PDR or TDR did not differ significantly between different groups with regard to gender, age, time since first HIV diagnosis, WHO stage, current CD4 cell count, ART status of sexual partner, history of PMTCT or HIV subtype (P . 0.05; data not shown).
Study limitations
See the Supplementary data available at JAC Online.
Conclusions
The WHO defined the threshold for triggering a public health response (the implementation of an NNRTI-free first-line regimen or PDR testing) as a 10% rate of PDR to NNRTIs. 20 Resistance rates to NNRTIs found in this and the other three recent studies from Tanzania are ,10%.
6-8 However, this is not a definite all-clear signal. None of the studies was generally representative of ART initiators in Tanzania and a recent systematic review found a universal increase in PDR rates over the last 20 years across 63 low-and middle-income countries. 3 This highlights the need for countrywide, systematic PDR surveillance in Tanzania. Rudovick et al.
